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Therapeutic Synergism Between Low-Dose FK 506 and 
Antimetabolites in Rat Allogeneic Heart Transplantation 
M. Tanabe, S. Todo, N. Murase, W. Irish, H. Miyazawa, S. Fujisaki, and T.E. Starzl 
FK 506 HAS HAD A major beneficial effect on the 
survival of transplanted organs. However. the use of 
FK 506 is limited by its toxicity. To circumvent this problem. 
we attempted to amplify the therapeutic efficacy of low-
dose FK 506 bv the combined use of various antimetabo-
lites, including' RS-61443 (RS),1 mizoribine (MIZ),2 and 
azathioprine (AZA). Therapeutic interaction was evaluated 
with rat allogeneic heart transplantation. 
MATERIALS AND METHODS 
Animals and Operation 
Inbred male Lewis (LEW. RTlI) and ACI rats (Rna) (Harlan 
Sprague· Dawley Inc. Indianapolis. Ind) served as recipients and 
donors. respectively. Cardiac allografting was performed by the 
method of Ono and Lindsay,3 and rejection was established by 
<:essation of heart beat followed by histologic examination. 
Immunosuppression 
All immunosuppressive regimens were continued for 14 days. 
starting on the day of heart transplantation. According to our 
previous report.· a daily dose of 0.04 mglkg was selected as a 
minimally effective dose of FK 506 berween no effect and clinical 
response. Serial oral doses of each antimetabolic drug from 
subclinical to lethal (shown in Table 1) were examined both as a 
monotherapy or in combination with 0.04 mg.'kg FK 506. RS-61443 
(Syntex Inc. Palo Alto. Calif) was used in a special vehicle (0.5% 
carboxymethylcellulose. 0.4% polysorbate !SO. 0.9% benzyl alcohol. 
Table 1. The Effect of Antimetabolite Treatment With 
or Without the Addition of FK 506 
AntimetabOhtes 
Imglkgld) 
MIZ 
AZA 
RS 
Median Graft SUrvival Days (n) 
Without 
FK 506" 
2.5 
5 
10 
15 
20 
30 
5 
30 
45 
60 
90 
20 
40 
60 
80 
9 
7 
9 
12 
15 
14 
8 
6 
11 
19 
11 
5 
13 
23 
19 
4 
With FK 
506" 
\11 ) 
IS) 
(6) 
(6) 
is) 
(5) 
(5) 
(5) 
(5) 
(5) 
(5) 
(4) 
(7) 
(6) 
(6) 
(4) 
CI 
6 (7) 
21' (7) 
19' (6) 
26' is) 
21 is) 
9 is) 
4 (5) 
11 (6) 
28' (5) 
32' (5) 
30 IS) 
6 is) 
22' (6) 
27 (5) 
13 (5) 
4 (4) 
0.64 
0.86 
0.70 
2.27 
0.75 
0.80 
1.00 
1.16 
'Survlval slgnlllcantly greater IP "-05) than tMt WIth antlmetaOOllte mono-
therapy and fixed low-dose FK 506 monolheraoy. 
alntramuscular FK 506 (0.04 mglkgld) for days 0 to 13. 
364 
and 0.9% sodium chloride in distilled water). Mizoribine (Bredinin. 
Asahi Chemical Industry Co Ltd .. Tokyo, Japan) and azathioprine 
were suspended in distilled water. 
Statistical Analysis 
The Mann-Whitney U test and/or Kruskall-Wallis test was used to 
analyse the survival difference between the treatment groups. The 
results were considered significant if P < .05. The interaction 
between FK 506 and these antimetabolites was assessed by the 
combination index (CI), which was calculated by the median effect 
analysis of Chou and Kahan.5•b CI values less than 1.0 suggest 
synergism: above 1.0 antagonism: and equal to 1.0 additivity. 
RESULTS 
With antimetabolite monotherapy, graft survival was pro-
longed with dose increments until this improvement was 
interrupted at higher doses by the mortality of overdosage. 
The peak median graft survival was 15 days for MIZ (15 
mglkg/d), 19 days for AZA (45 mg/kg/d), and 23 days for RS 
(40 mg/kg/d). The difference was significant between RS 
and MIZ (P = .04) but not between RS and AZA. 
Indefinite graft survival (> 100 days) in two experiments was 
achieved only with 60 mg/kg/d RS. 
All antimetabolites when added to low-dose FK 506 
provided better results at some doses (P < .05) than when 
low-dose FK 506 or antimetabolite was given alone. This 
was accomplished at doses of 2.5, 5.0, and 10.0 mg/kg/d 
MIZ, 30 and 45 mg;kg/d AZA. and 20 mg/kg/d RS. Among 
these combined therapy groups. the peak median survival of 
32 days using 45 mg;kg/d AZA was significantly longer than 
that of MIZ (26 days at 10 mg;kg/d MIZ. P = .03) or RS (27 
days at 40 mg/kg/d RS. P = .43). 
The CI between each dose of antimetabolite and FK 506 
was calculated from forgoing data excluding toxic doses of 
antimetabolite (no higher than the doses with peak median 
survival). These were 0.64 to 0.H6 for MIZ. 0.75 to 2.27 for 
AZA' and 1.00 to 1.16 for RS. 
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THERAPEUTIC SYNERGISM 
DISCUSSION 
1\ oenefit of combined immunosuppressive therapy with 
hlW.dose FK 506 and antimetabolites for heart transplan-
tation from ACI to LEW rats was clearly shown in this 
~fudyK Therapeutic synergism was present when FK 506 was 
((1'''' lined with either MIZ (2.5, 5.0. and 10 mglkgld) or 
AI. \ (30. 45 mglkg/d), whereas RS interacted with FK 506 
no morc than additively. It is worth noting that therapeutic 
synergism with low-dose FK 506 was particularly pro-
~ounccd at the subclinical dose of MIZ (2.5 mg/kg/d). Of 
the thrce anti metabolites, RS gave the best graft survival 
when used alone. but the best overall result was obtained by 
comhining AZA and FK 506. 
A conventional explanation for drug synergism is the 
different site of action of the combined agents. Suppression 
of allospecific T-cell immunity by FK 506 is explained by 
inhihition of the production of IL-2 and its receptor expres-
slon.7 In contrast. MIZ. AZA, and RS inhibit purine 
Olllwnlhesis. curtailing the DNA synthesis necessary for cell 
dll·"I(IIl. including that of activated T and B lympho· 
365 
cytes.I.2·11 Synergism resulting from these diverse antilym-
phocytic mechanisms has been observed in vitro.'} and its 
clinical utility was supported by the in vivo results of this 
study. 
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